Trial Profile

A RANDOMIZED PHASE-II CLINICAL TRIAL TO EVALUATE THE EFFECT OF PIRFENIDONE COMPARED WITH PLACEBO IN PULMONARY FIBROSIS POST-COVID 19

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pirfenidone (Primary)
Indications COVID-19 pneumonia; Pulmonary fibrosis; SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use
Acronyms FIBRO-COVID

Most Recent Events

13 Sep 2023 Status changed from recruiting to completed according to Results presented at the 33rd Annual Congress of the European Respiratory Society.
13 Sep 2023 Primary endpoint (To investigate the effect of pirfenidone on fibrotic signs induced by COVID19 infection) has not been met according to
13 Sep 2023 Results presented at the 33rd Annual Congress of the European Respiratory Society

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com